MedTrace Logo

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

NCT02336386 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-01-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.

Conditions

  • Extramedullary Plasmacytoma

Interventions

DRUG

CDD

Chemotherapy

DRUG

CDD Plus Bortezomib

Chemotherapy plus Proteasome Inhibitors

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Beijing Chao Yang Hospital

    lead OTHER

Principal Investigators

  • Yuping Zhong, Doctor · Beijing Chao Yang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02336386 on ClinicalTrials.gov